EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSMZEG00005024159
Gene Symbol: PSMD8
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-5-Like

Ensembl ID : ENSMZEG00005021698
Gene Symbol: LOC112434037
4 Cross references
210 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSMZEG00005008153
Gene Symbol: LOC101483887
3 Cross references
244 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSMZEG00005006083
Gene Symbol: LOC101465041
3 Cross references
278 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSMZEG00005012375
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSMZEG00005020666
Gene Symbol: LOC101481073
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-5

Ensembl ID : ENSMZEG00005013801
Gene Symbol: LOC101485859
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-6

Ensembl ID : ENSMZEG00005027682
Gene Symbol: LOC101466438
3 Cross references
230 Possible Orthologues:

Proteasome Subunit Beta Type-7

Ensembl ID : ENSMZEG00005009082
Gene Symbol: LOC101476664
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-7

Ensembl ID : ENSMZEG00005009482
Gene Symbol: LOC101471805
3 Cross references
216 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSMZEG00005023957
Gene Symbol: LOC101472230
3 Cross references
208 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSMZEG00005012334
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).